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internalisation, whereas multiple monoclonal antibodies lead to
efficient internationalisation by formation of an antigen–antibody
lattice at the cell surface.
An example was shown that involved combining two mono-
clonal antibodies, trastuzumab and pertuzumab, which do not
compete for the same HER-2 site. The combination was much
more effective than either used alone.
DEVELOPMENT OF RESISTANCE TO ANTI-ERBB RECEPTOR
ANTIBODIES: Only a third of breast cancer patients with Her-2
overexpressing tumours respond initially to trastuzumab, imply-
ing that most patients have primary resistance. Also the majority
of responding patients demonstrate disease progression after
months of treatment initiation because they develop secondary
resistance. Nagata et al. described the development of resistance
to monoclonal antibodies via deficiency of PTEN, a dual phospha-
tase that mainly dephosphorylates position D3 of membrane
phosphatidylinositol-3,4,5 trisphosphate. PTEN-deficient breast
cancer patients had significantly poorer responses to trast-
uzumab-based therapy than those with normal PTEN levels.
The authors concluded that PTEN deficiency predicted resistance
to trastuzumab and that PI3K inhibitors rescued PTEN loss-
induced trastuzumab resistance in a model system, suggesting
PI3K-targeting therapies as a means of overcoming acquired
resistance.4
Another possible mechanism for resistance to monoclonal
antibodies against tyrosine kinase receptors was described by
Nagy et al. who claimed that MUC4, a membrane-associated gly-
coprotein that inhibits trastuzumab binding to Her-2, was higher
in a trastuzumab-resistant cell line than in sensitive cell lines.5
Levels of MUC4 were inversely correlated with the trastuzumab-
binding capacity of single cells. Knockdown of MUC4 expression
by RNA interference increased binding. It is postulated that mask-
ing of ErbB2 by MUC4 is a mechanism for trastuzumab resistance.
In addition resistance may occur via insulin-like growth factor-I
(IGF-I) receptor interactions, as described by Nahta and col-
leagues.6 They found that Her-2 interacts in a unique way with
IGF-I receptor in trastuzumab-resistant cells possibly enabling
cross talk between IGF-I receptor and Her-2. The IGF-I receptor/
Her-2 heterodimer could contribute to trastuzumab resistance
and serve as a potential therapeutic target in breast cancer
patients whose disease has progressed while on trastuzumab.5
In conclusion, defective immune responses (e.g. Fc receptors)
might underlie primary resistance to trastuzumab, but acquired
(secondary) resistance seems to involve compensatory signalling
mechanisms.
Various reports have addressed the issue of resistance to tyro-
sine kinase inhibitors (TKI). Despite significant responses to gefi-
tinib (Iressa), most patients with non-small-cell lung cancer
(NSCLC) relapse after 6–18 months. Kobayashi et al. described
the case of a patient with EGFR-mutant, gefitinib-responsive,
advanced NSCLC who relapsed after 2 years of complete remis-
sion. Secondary resistance developed via a second point mutation
in EGFR.7 This phenomenon might be responsible for germ-line
mutations in families with multiple cases of NSCLC. It is not
known whether this mutation exists independent of gefitinib
exposure. Acquired resistance to lapatinib was associated with
up-regulation of oestrogen receptor signalling.8 These findings
appear to provide a rationale for preventing the development of
acquired resistance by simultaneously inhibiting both oestrogen
receptor and ErbB2 signalling pathways.
In summary tumours demonstrate remarkable plasticity,
seeming to switch pathways when one is effectively inhibited.
Clarifying the mechanisms of drug action is critical for under-
standing resistance to targeted therapies. Resistance mecha-
nisms richly harness compensatory pathways (PI3K/Akt, Her-3
and IGF-I receptor). Understanding drug resistance will likely
identify novel drug combinations and elucidate the mechanisms
of tumour cell escape, which must involve the ability to up-regu-
late certain pathways.
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In future, proteomics biomarkers may be used involving a novel
technique for studying protein–protein interactions, and high-
throughput and high-content imaging methods. Light, being of
zero mass and unmatched in speed, is an efficient means of send-
ing information to and from structures and materials. Therefore,
optical imaging methods, with the aid of suitable contrast-gener-
ation biomarkers, are appropriate to conveying a great deal of
information about tumours cells and tissues, and their response
to targeted therapies.
A recently formed Optical Proteomics Consortium (http://
www.opticalproteomics.org) is a research network dedicated to
developing new optical technologies for monitoring protein inter-
actions and post-translational modifications in cells and tissues.
Its goal is to advance understanding of the function of proteins
and to determine protein interactions and interaction networks
in situ. It aims to develop techniques that are complementary to
established, but more indirect methods (e.g. matrix-assisted
desorption/ionisation time-of-flight (MALDI-TOF) mass spec-
trometry) that enable the analysis and identification of very small
amounts of protein. In contrast, optical techniques are in situ
methods which perform the analyses in a physiological context.
ROLE OF PROTEOMICS AND FUNCTIONAL GENOMICS IN BREAST
CANCER: Breast cancer treatment involves surgical excision,
cytotoxic chemotherapy, radiotherapy, hormonal manipulation
and targeted biologic agents. Breast cancer patients face a great
diversity of possible clinical outcomes and vary widely in the ben-
efits, risks and toxicities deemed acceptable. Current prognostic
features estimate the risk of recurrence for groups only; ideally,
however, we would like to be able to identify genetic and proteo-
mic profiles that could predict aggressive behaviour of breast can-
cer cells in individuals and be associated with specific outcomes.
Despite the availability of established methods for genomic
profiling via gene expression arrays, there is limited evidence
which suggests that treatment decisions based on such profiles
save lives. The specificity of therapeutic agents is determined by
their effect on the proteome, involving multiple proteins and pro-
tein networks. Protein function depends on post-translational
modification, glycosylation, phosphorylation and so forth. One
of the goals of a current proteomic study is to process as many
archived cancer tissues as possible in an attempt to correlate tis-
sue microarray (TMA) results with clinical outcomes. If a link is
found between one or more markers and clinical outcomes, pro-
spective studies could be carried out.
Fluorescence lifetime imaging (FLIM)
Studies are ongoing that investigate whether a strong interaction
between PKC-a and ezrin in breast cancer tissue confers on a
tumour an increased ability to survive and metastasise. PKC-a is
a signalling protein that opposes apoptosis and is implicated in
tumour progression. As previously shown,1 using in vitro systems,
ezrin is a protein that provides a direct link between the cytoskel-
eton and the plasma membrane. An extension of this method
involves fluorescent-labelled antibodies applied to tumour micro-
arrays (TMAs), which are then analysed using fluorescence life-
time imaging (FLIM). Interactions are quantified using Fo¨rster
resonant energy transfer (FRET), a very powerful tool capable of
quantifying protein interactions.2 FRET relies on the presence of
two fluorescent tags, a donor and an acceptor molecule. It
requires labelling of target proteins with specific fluorescent tags,
via either genetic encoding or chemical means. When the donor
molecule is excited with a short light pulse of appropriate wave-
length, its fluorescence emission profile is modified by the pres-
ence, or otherwise, of the acceptor molecule. When energy is
transferred from a donor molecule to the acceptor, the donor
emission is quenched and this is reflected in the reduction of
the donor fluorescence lifetime: the interaction causes energy
to be transferred from the donor fluorophores to acceptor fluoro-
phores, producing increased emission from the acceptor and a
decreased fluorescence lifetime in the donor.3 A histogram of
the arrival times of photons from the donor can then be com-
piled. The lifetime is defined as the average amount of time a
molecule spends in an excited state following absorption of light.
Fluorescence lifetimes range from pico- to nanoseconds and, in
this instance, indicate how close the two proteins are; the relative
amplitudes of the quenched and unquenched lifetimes give a
measure of how many donor–acceptor pairs are present. FRET
only occurs when the two spectrally overlapping fluorophores
are in close proximity to one another (typically < 10 nm).
Although such techniques are well established,4–8 for studying
cellular systems in vitro, the technological challenge is to scale
them up to allow quantification of significant imaged areas,
involving a large number of cells. This technique was used on
breast tissue TMA samples to study differences in protein interac-
tion in basal cell invasive cancer. For example, in normal basal
duct epithelium, no FRET occurs; that is, ezrin and PKC-a do not
interact. In grade 2 invasive ductal breast cancer, however, such
an interaction does occur and FRET is present. This study was per-
formed using antibodies to ezrin (2H3, Cy2-labelled) and to PKC-a
(T(P)250, Cy3-labelled) and was based on an 84 section TMA per
slide. Currently, lifetime distributions give a clear distinction
between FRET and control sections at around 1.5 and 1.8 ns aver-
age lifetimes, respectively. A range of software tools is employed
to provide detailed kinetic analyses and results where the distri-
bution of errors is understood. In particular, the use of ‘global’ fit-
ting algorithms allows a greater ‘contrast’ to be obtained between
control (ca. 1.8 ns) and FRET-ing areas (exhibiting mixtures of
1.8 ns and ca. 500 ps).9 Nevertheless, to make such a study most
effective, tissue areas that are not contributing to the signal
would ideally be excluded by software tools that highlight, either
manually or by automated means, specific areas of interest. Such
approaches minimise the contributions from, e.g. autofluro-
scence emissions, and thus provide a more valid contribution
from the proportions of tissues exhibiting FRET. Manual delinea-
tion of specific areas inevitably introduces an operator-dependent
bias, as well as slowing down analyses and to this end, various
automated methods, based on techniques used in pathology to
grade tissue sections are under development. In particular, the
texture of the imaged sample gives a great deal of information
and Prof. Vojnovic described a method for automated texture
analysis that classifies images using a range of measures. He
showed an example in which the imaging system ‘looks’ at
extreme cases of distinct textures, aided initially by a trained
observer, then uses a range of measures classified in a multidi-
mensional vector space and analyses them to identify specific
regions of interest (e.g. membrane-bound staining, regions of
invasive tumour edge, cytoplasmic areas, etc.) to determine sepa-
rate FRET patterns within these.
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Further developments in instrumentation to acquire data
from a complete TMA are necessary. Conventional microscopy
methods must be significantly adapted to acquire, in an unsuper-
vised manner, images from the complete array, as is required to
preserve spatial information and relationships. Large numbers
of images are eventually ‘stitched’ together to provide a complete
image. Continuous automatic focusing methods are essential to
preserve sub-cellular resolutions. Although the work is currently
slow, results are very precise and accurate.
THE FUTURE: Currently, we are moving away from normal
microscopy platforms for this type of work. Under development
is a prototype imaging station dedicated to high-throughput
work. This arrangement eliminates traditional approaches and
is equally suited to acquiring data from other ‘large-area’ sam-
ples. An obvious example is the use of high-density multiwell
plates for assays involving drug action. One of the current rate-
limiting steps is the use of scanned optical beams and single-
point detection.10–13 Highly parallel time-resolved detectors are
however under development and the future of this technique will
be dependant on complementary highly parallel signal process-
ing instrumentation. Furthermore, data handling and analysis
requires multiprocessor computer architectures and a high level
of automation.
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Matrix-assisted laser desorption/ionisation (MALDI) is a ‘soft’ ion-
isation technique that most often uses a time-of-flight (TOF) mass
spectrometer. The advantage of MALDI-TOF TOF mass spectrom-
etry (MS) over alternative approaches are ease of use, simple sam-
ple preparation and high throughput, rendering it an ideal tool for
large scale clinical application.1 Using MALDI-TOF MS for clinical
specimens can yield important information about disease state,
drug response and/or efficacy, and drug toxicities. It can also be
used to analyse biomolecules that could serve as classifiers to
determine which patients will most likely respond to certain
molecularly targeted therapies. The use of MALDI-TOF MS as a
clinical tool has been overshadowed by some notable failures.
Focusing on reproducibility and validation, we have shown that
MALDI-TOF MS can be successfully applied to protein profiling
in a clinical setting.
MASS SPECTROSCOPY AS A DIAGNOSTICS TOOL: Achieving
sufficient reproducibility in mass spectrometry for use in a clini-
cal setting is hardly a trivial issue. Mass spectra can be highly var-
E J C S U P P L E M E N T S 5 ( 2 0 0 7 ) 1 8 –2 2 21
